Stock Research: Surmodics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Surmodics

NasdaqGS:SRDX US8688731004
4
  • Value
    65
  • Growth
    3
  • Safety
    Safety
    36
  • Combined
    11
  • Sentiment
    16
  • 360° View
    360° View
    4
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Surmodics, Inc. provides performance coating technologies for medical devices and chemical/biological components for in vitro diagnostic tests, also developing vascular intervention medical devices. It operates in the Medical Device and IVD segments, serving neurovascular, peripheral, coronary, diagnostic, and biomedical research markets. In the last fiscal year, the company had a market cap of $451 million, profits of $93 million, revenue of $126 million, and 389 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 4 (better than 4% compared with alternatives), overall professional sentiment and financial characteristics for the stock Surmodics are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Surmodics. The only rank that is above average is the consolidated Safety Rank at 65, which means that the company has a financing structure that is safer than those of 65% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 36, which means that the share price of Surmodics is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 3, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 16, which means that professional investors are more pessimistic about the stock than for 84% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
36 45 28 13
Growth
3 83 53 3
Safety
Safety
65 73 37 82
Sentiment
16 16 67 34
360° View
360° View
4 59 33 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
1 7 97 96
Opinions Change
50 92 50 50
Pro Holdings
n/a 4 52 6
Market Pulse
56 50 23 25
Sentiment
16 16 67 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
36 45 28 13
Growth
3 83 53 3
Safety Safety
65 73 37 82
Combined
11 93 17 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
38 38 15 15
Price vs. Earnings (P/E)
43 45 40 40
Price vs. Book (P/B)
48 51 42 36
Dividend Yield
1 1 1 1
Value
36 45 28 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
10 39 84 9
Profit Growth
38 96 4 1
Capital Growth
13 75 62 11
Stock Returns
23 57 63 63
Growth
3 83 53 3
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
69 70 60 73
Refinancing
47 49 27 19
Liquidity
35 47 50 89
Safety Safety
65 73 37 82

Similar Stocks

Discover high‑ranked alternatives to Surmodics and broaden your portfolio horizons.

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.